Padma Sundar

Padma Sundar is VP of Strategy and Market Access at CallMax Life, a liquid biopsy company focused on cancer screening with a proprietary technology for detecting precancer and cancer cells in a single blood sample. Sundar is responsible for corporate strategy, market access and marketing at CellMax Life. She has over 20 years of experience commercializing and driving adoption of novel diagnostics. Prior to CellMax, Sundar led product management and marketing for Guardant Health's liquid biopsy, leading to its adoption by 80% of oncologists in the United States. Sundar also led product management at Roche Sequencing for their liquid biopsy tests, which have been launched in over 50 countries worldwide for cancer treatment selection and monitoring. Sundar began her career at McKinsey & Company?s healthcare practice. She has an MBA-MPH from UC Berkeley and a Bachelors in Chemistry.